<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05027529</url>
  </required_header>
  <id_info>
    <org_study_id>ZKSJ0131</org_study_id>
    <secondary_id>DRKS00025265</secondary_id>
    <nct_id>NCT05027529</nct_id>
  </id_info>
  <brief_title>ECMOsorb Trial - Impact of a VA-ECMO in Combination With CytoSorb in Critically Ill Patients With Cardiogenic Shock</brief_title>
  <acronym>ECMOsorb</acronym>
  <official_title>ECMOsorb Trial - Impact of a VA-ECMO in Combination With CytoSorb in Critically Ill Patients With Cardiogenic Shock- A Prospective, Randomized, Blinded, Monocenter Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Christian Schulze</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jena University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the ECMOsorb study the impact of a veno-arterial -ECMO in combination with an&#xD;
      extracorporeal cytokine hemadsorption system in critically ill patients with cardiogenic&#xD;
      shock is to be examined&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prospective, interventional, randomised controlled and blinded ECMOsorb study&#xD;
      investigates in critically ill patinets with cardiogenic shock and with veno-arterial ECMO&#xD;
      (VA-ECMO) treatment the impact of an extracorporeal cytokin hemadsorption system on&#xD;
      hemodynamics, defined by the Inotropic Score 72 hours after initiation of the adsorber&#xD;
      (intervention) or normal ECMO tube (control) in the VA-ECMO.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 21, 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>prospective, randomized, controlled, blinded, monocenter trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>masking by using a &quot;black-box&quot;; the control group only receives a regular ECMO tube</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in inotropic score after 72h (difference between the two study groups)</measure>
    <time_frame>72 hours</time_frame>
    <description>Inotropic Score: dopamine dose [μg/kg/min] + dobutamine dose [μg/kg/min] + 100x epinephrine dose [μg/kg/min] + 100x norepinephrine [μg/kg/min]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Interleukin 6</measure>
    <time_frame>0 to 7 days after beginning of intervention</time_frame>
    <description>pg/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procalcitonin</measure>
    <time_frame>0 to 7 days after beginning of intervention</time_frame>
    <description>ng/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>c-reactive protein</measure>
    <time_frame>0 to 7 days after beginning of intervention</time_frame>
    <description>mg/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lactate</measure>
    <time_frame>0 to 7 days after beginning of intervention</time_frame>
    <description>mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>creatinine</measure>
    <time_frame>0 to 7 days after beginning of intervention</time_frame>
    <description>µmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glomerular filtration rate (GFR)</measure>
    <time_frame>0 to 7 days after beginning of intervention</time_frame>
    <description>ml/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>troponin</measure>
    <time_frame>0 to 7 days after beginning of intervention</time_frame>
    <description>pg/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>creatinine kinase</measure>
    <time_frame>0 to 7 days after beginning of intervention</time_frame>
    <description>µmol/l*s</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>myoglobine</measure>
    <time_frame>0 to 7 days after beginning of intervention</time_frame>
    <description>µg/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urinary output</measure>
    <time_frame>0 to 7 days after beginning of intervention</time_frame>
    <description>ml/h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neuron specific enolase</measure>
    <time_frame>0 to 7 days after beginning of intervention</time_frame>
    <description>µg/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>s-100</measure>
    <time_frame>0 to 7 days after beginning of intervention</time_frame>
    <description>µg/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cystatin c</measure>
    <time_frame>0 to 7 days after beginning of intervention</time_frame>
    <description>mg/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>galectin-3</measure>
    <time_frame>0 to 7 days after beginning of intervention</time_frame>
    <description>ng/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of: renal replacement therapy (CVVHD), mechanical ventilation, ECMO therapy, inotropic /vasopressor treatment</measure>
    <time_frame>day 30 after beginning of intervention</time_frame>
    <description>hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30 day, ICU and in-hospital mortality</measure>
    <time_frame>day 30 after beginning of intervention</time_frame>
    <description>nominal scale (yes/no)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in ICU and total length of hospital stay until discharge/transfer</measure>
    <time_frame>day 30 after beginning of intervention</time_frame>
    <description>hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Necessary Implantation of an Active Assist Device or heart transplantation</measure>
    <time_frame>day 30 after beginning of intervention</time_frame>
    <description>nominal scale (yes/no)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAPS II</measure>
    <time_frame>0 to 7 days after beginning of intervention</time_frame>
    <description>Simplified Acute Physiology Score II (Minimum value: 0 / maximum value: 163; higher values means worse outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>APACHE II score</measure>
    <time_frame>0 to 7 days after beginning of intervention</time_frame>
    <description>Acute Pysiology and Chronic Health Evaluation II (Minimum value: 0 / maximum value: 71; higher values means worse outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA score</measure>
    <time_frame>0 to 7 days after beginning of intervention</time_frame>
    <description>Sequential Organ Failure Assessment Score (Minimum value: 0 / maximum value: 24; higher value means worse outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cerebreal performance category (CPC)</measure>
    <time_frame>0 to 30 days after beginning of intervention</time_frame>
    <description>CPC 1 (adequate function) to CPC 5 (brain dead)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glasgow coma scale (GCS)</measure>
    <time_frame>0 to 30 days after beginning of intervention</time_frame>
    <description>Assessment scheme for disorders of consciousness and brain function (eyes, verbal, motor); scale from 3 (severe impairment) to 15 points (no abnormalities)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQuol 5D-3L Descriptive System</measure>
    <time_frame>7 to 30 days after beginning of intervention</time_frame>
    <description>mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ VAS</measure>
    <time_frame>7 to 30 days after beginning of intervention</time_frame>
    <description>EQ visual analogue scale (EQ VAS), patient's self-rated health on a vertical visual analogue scale where the endpoints are labelled 'Best imaginable health state' and 'Worst imaginable health state'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin scale</measure>
    <time_frame>0 to 30 days after beginning of intervention</time_frame>
    <description>scale from 0 (no symptoms) to 6 (dead);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of right ventricular parameters</measure>
    <time_frame>0 to 7 days after beginning of intervention</time_frame>
    <description>measurements of right ventricular function in the echo (TAPSE in mm; FAC in %; RVEDD in mm; sPAP in mmHg; RA area in cm²; TASV in cm/s; ICV in mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of left ventricular parameters</measure>
    <time_frame>0 to 7 days after beginning of intervention</time_frame>
    <description>measurements of left ventricular function in the echo (LVEDD in mm; LVESD in mm; LVEF in %; VSD (yes/no); LVEDV in ml; LVESV in ml; GLS in %; LA volume in ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of kidney injury and kidney function</measure>
    <time_frame>0 to 7 days after beginning of intervention</time_frame>
    <description>NGAL, KIM-1, L-FABP, IGFBP7 in ng/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin 18</measure>
    <time_frame>0 to 7 days after beginning of intervention</time_frame>
    <description>pg/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of apoplexy</measure>
    <time_frame>30 days after beginning of intervention</time_frame>
    <description>nominal scale (yes/no)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean arterial pressure</measure>
    <time_frame>0 to 7 days after beginning of intervention</time_frame>
    <description>mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>central venous oxygen saturation</measure>
    <time_frame>0 to 7 days after beginning of intervention</time_frame>
    <description>in %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mixed venous oxygen saturation</measure>
    <time_frame>0 to 7 days after beginning of intervention</time_frame>
    <description>in %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>arterial oxygen saturation</measure>
    <time_frame>0 to 7 days after beginning of intervention</time_frame>
    <description>in %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>heart failure re-hospitalisation</measure>
    <time_frame>30 days after beginning of intervention</time_frame>
    <description>nominal scale (yes/no)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain natriuretic peptide (BNP)</measure>
    <time_frame>0 to 7 days after beginning of intervention</time_frame>
    <description>pg/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>n-terminal pro brain natriuretic peptide (NT-proBNP)</measure>
    <time_frame>0 to 7 days after beginning of intervention</time_frame>
    <description>pg/ml</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Cardiogenic Shock</condition>
  <arm_group>
    <arm_group_label>VA-ECMO and CytoSorb</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>standard ICU care WITH CytoSorb</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VA-ECMO only</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>standard ICU care WITHOUT CytoSorb</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CytoSorb</intervention_name>
    <description>An extracorporeal cytokine hemoadsorption system is integrated in the VA-ECMO circuit</description>
    <arm_group_label>VA-ECMO and CytoSorb</arm_group_label>
    <other_name>Standard ICU care (with VA-ECMO) AND CytoSorb Adsorber</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>VA-ECMO only</intervention_name>
    <description>only VA-ECMO; NO extracorporeal cytokine hemoadsorption system is added</description>
    <arm_group_label>VA-ECMO only</arm_group_label>
    <other_name>Standard ICU care (with VA-ECMO)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cardiogenic shock of any cause and indication for VA-ECMO&#xD;
&#xD;
          -  Age between 18 and 80&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current participation in another interventional trial&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Current immunosuppressive or immunomodulatory therapy&#xD;
&#xD;
          -  Contraindications to VA-ECMO implantation.&#xD;
&#xD;
          -  Patients with pre - existing sepsis (raised CPR, positive PCT, leukozytosis, fever,&#xD;
             positive blood cultures).&#xD;
&#xD;
          -  Shock duration&gt; 12 h before evaluation.&#xD;
&#xD;
          -  Severe PVD (peripheral vessel disease) making ECMO-implantation impossible.&#xD;
&#xD;
          -  Aortic valve insufficiency / stenosis at least II °.&#xD;
&#xD;
          -  Age &gt; 80 years.&#xD;
&#xD;
          -  CNS disease with fixed, dilated pupils (not drug-induced).&#xD;
&#xD;
          -  Severe concomitant disease with limited life expectancy &lt;6 months.&#xD;
&#xD;
          -  CPR&gt; 60min.&#xD;
&#xD;
          -  Shock due to other reasons&#xD;
&#xD;
          -  HIT positive (Heparin induced thrombocytopenia)&#xD;
&#xD;
          -  Very low platelet counts (&lt; 20,000/µl)&#xD;
&#xD;
          -  Body weight less than 45 kg&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Schulze, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Jena University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christian Schulze, Prof.</last_name>
    <phone>004936419324100</phone>
    <email>Christian.Schulze@med.uni-jena.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Franz Haertel, Dr.</last_name>
    <phone>004936419324554</phone>
    <email>Franz.Haertel@med.uni-jena.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jena University Hospital, Department of Cardiology</name>
      <address>
        <city>Jena</city>
        <state>Thuringia</state>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Schulze, Prof.</last_name>
      <phone>+4936419324100</phone>
      <email>Christian.Schulze@med.uni-jena.de</email>
    </contact>
    <contact_backup>
      <last_name>Franz Haertel, Dr.</last_name>
      <phone>+4936419324554</phone>
      <email>Franz.Haertel@med.uni-jena.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 12, 2021</study_first_submitted>
  <study_first_submitted_qc>August 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2021</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Jena University Hospital</investigator_affiliation>
    <investigator_full_name>Christian Schulze</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>cardiogenic shock</keyword>
  <keyword>VA-ECMO</keyword>
  <keyword>venous arterial Extracorporeal Membrane Oxygenation</keyword>
  <keyword>inotropic score</keyword>
  <keyword>extracorporeal cytokine hemadsorption system</keyword>
  <keyword>cytokine adsorber</keyword>
  <keyword>intensive care</keyword>
  <keyword>multi organ failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Cardiogenic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

